METHOD AND SYSTEM FOR DETECTING AND IDENTIFYING ACUTE STRESS RESPONSE FROM TRAUMATIC EXPOSURE, ITS TRANSITION TO POST TRAUMATIC STRESS DISORDER, AND MONITORING SUBSEQUENT THERAPY
The present invention relates to a method and system for using neurochemical markers to enable whether a subject is experiencing acute stress, trauma, or PTSD and providing the capacity to monitor response to therapy on an individual basis. The markers can be an increase of NAA, glutamine or Fuc IV and lactate and a decrease of Fuc IV during the transition from acute stress to PTSD.
1 . A method for enabling detection of whether a subject is experiencing acute stress, trauma-exposure or PTSD, comprising:
obtaining MR spectral data from a subject's brain tissue using a MR spectroscopy device; and
producing, from the MR spectra obtained, spectral data which enables the detection of whether the subject is experiencing acute stress, trauma-exposure or PTSD by detecting the presence of at least one neurochemical marker, and comparing the detected amount of neurochemical marker with reference amounts for healthy persons.
2 . The method of claim 1 , wherein the MR data is obtained using 2D COSY.
3 . The method of claim 1 , wherein an increase of at least one of N-Acetylaspartate and glutamate enables the detection of whether the subject is experiencing acute stress or trauma-exposure.
4 . The method of claim 1 , wherein an increase of Fuc IV and lactate enables the detection of whether the subject is experiencing PTSD.
5 . The method of claim 1 , wherein an increase of Fuc IV and lactate, and a decrease of Fuc VI, enables the detection of whether the subject is experiencing acute stress, trauma-exposure or PTSD.
6 . The method of claim 1 , including treating the patient with a treatment protocol to mitigate acute stress, trauma-exposure, or PTSD.
7 . The method of claim 6 , where in the treatment protocol includes physiotherapy.
8 . The method of claim 1 , wherein the steps of obtaining and producing are repeated after a time interval to monitor the progress of a treatment protocol.
9 . The method of claim 8 , wherein the time interval is about 4 weeks.
10 . The method of claim 1 , wherein the steps of obtaining and producing and repeated multiple times after time intervals, to monitor the progress of a treatment protocol.
11 . The method of claim 1 , wherein at least one of the steps of producing, detecting and comparing is performed in a remote location from the obtaining step.
12 . The method of claim 11 , wherein the remote location is the cloud.
13 . A method for enabling detection of whether a subject is experiencing acute stress, trauma-exposure or PTSD, comprising:
obtaining MR spectral data from a subject's brain tissue using a MR spectroscopy device and 2D COSY; and
producing, from the MR spectra obtained, spectral data which enables the detection of whether the subject is experiencing acute stress, or trauma-exposure or PTSD by detecting the presence of at least one neurochemical marker, and comparing the detected amount of neurochemical marker with reference amounts for healthy persons.
14 . The method of claim 13 , wherein the at least one neurochemical marker is at least one of NAA and glutamate.
15 . The method of claim 13 , wherein the steps of obtaining and producing are repeated after a time interval to monitor the progress of a treatment protocol.
16 . The method of claim 13 , wherein the time interval is about 4 weeks.
17 . The method of claim 13 , wherein the steps of obtaining and producing are repeated multiple times after time intervals, to monitor the progress of a treatment protocol.
18 . A system for obtaining at least one neurochemical marker to enable detection of whether a subject is experiencing acute stress, trauma-exposure or PTSD, comprising:
a magnetic spectroscopy device for obtaining MR spectral data from a subject's brain tissue; and
a comparator for comparing the amount of at least one neurochemical marker obtained with reference amounts for healthy persons to enable a determination of whether the subject is whether a subject is experiencing acute stress, trauma-exposure or PTSD.
19 . The system of claim 18 , wherein the at least one neurochemical marker is at least one of NAA and glutamate.
20 . The system of claim 18 , wherein the acute stress or trauma-exposure which can be detected is lower back anxiety or trauma.
21 . The system of claim 18 , wherein the MR data is obtained using 2D COSY.
22 . The system of claim 18 , wherein an increase of Fuc IV and lactate enables the detection of whether the subject is experiencing acute stress, trauma-exposure or PTSD.
23 . The system of claim 18 , wherein a decrease in Fuc VI enables the detection of whether the subject is experiencing acute stress, or trauma-exposure or PTSD.
24 . The system of claim 18 , wherein an increase of Fuc IV and lactate, and a decrease of Fuc VI, enables the detection of whether the subject is experiencing acute stress or trauma.
25 . The system of claim 18 , including a memory for storing MR data obtained during different time intervals to monitor the progress of a treatment protocol.
26 . The system of claim 25 , the time interval is about 4 weeks.
27 . The system of claim 25 , wherein the memory stores MR data obtained multiple times after at least two time intervals, to monitor the progress of atreatment protocol.
28 . The system of claim 18 , wherein the comparator is located at a location remote from the magnetic spectroscopy device.
29 . The system of claim 28 , wherein the comparator is located in the cloud.
30 . A non-transitory computer readable storage medium for storing executable instructions for performing the following steps, to enable detection of whether a subject is experiencing acute stress or trauma:
obtaining MR spectral data from a subject's brain tissue using a MR spectroscopy device; and
producing, from the MR spectra obtained, spectral data which enables the detection of whether the subject is experiencing acute stress, trauma-exposure or PTSD by detecting the presence of at least one neurochemical marker, and comparing the detected amount of neurochemical marker with reference amounts for healthy persons.
31 . The storage medium of claim 30 , wherein the MR data is obtained using 2D COSY.
32 . The storage medium of claim 30 , wherein the neurochemical marker is at least one of N-Acetylasparte and glutamate.
33 . The storage medium of claim 30 , wherein the neurochemical marker is at least one of Fuc IV, lactate and Fuc VI.